Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Climb Bio (CLYM) Non Operating Income (2020 - 2026)

Climb Bio filings provide 7 years of Non Operating Income readings, the most recent being $1.5 million for Q1 2026.

  • Quarterly Non Operating Income fell 33.44% to $1.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Mar 2026, down 19.53% year-over-year, with the annual reading at $8.0 million for FY2025, 1.12% down from the prior year.
  • Non Operating Income hit $1.5 million in Q1 2026 for Climb Bio, down from $1.8 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $2.8 million in Q3 2024 and bottomed at -$934000.0 in Q3 2022.
  • Average Non Operating Income over 5 years is $1.3 million, with a median of $1.5 million recorded in 2026.
  • The largest annual shift saw Non Operating Income tumbled 7358.33% in 2022 before it surged 1694.44% in 2023.
  • Climb Bio's Non Operating Income stood at $1.8 million in 2022, then fell by 17.35% to $1.5 million in 2023, then surged by 68.47% to $2.5 million in 2024, then fell by 28.66% to $1.8 million in 2025, then fell by 16.35% to $1.5 million in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Non Operating Income are $1.5 million (Q1 2026), $1.8 million (Q4 2025), and $2.0 million (Q3 2025).